This Program Announcement expires on January 2004 unless reissued. SBIR/STTR TECHNOLOGIES FOR MONITORING AND PERFORMING RESUSCITATION Release Date: February 16, 2001 PA NUMBER: PA-01-054 National Heart, Lung, and Blood Institute (http://www.nhlbi.nih.gov) PURPOSE This announcement is to encourage small businesses to participate in the research and development of new approaches, tools, methods, devices, and biomaterials to provide bioengineering-based methodologies for monitoring and performing resuscitation. Ultimately, the goal of this program is to reduce morbidity and mortality from circulatory, hypoxemic or traumatic arrest. For this purpose, this announcement is interested in fostering better systems and methods for out-of-hospital and basic resuscitation research that 1) enables monitoring of genetic, molecular, biochemical, physical or metabolic derangements associated with circulatory, hypoxemic, or traumatic arrest; and 2) elucidates the unique pathophysiology of irreversible injury following multiple organ or whole-body ischemia and reperfusion, Applications should address critical cardiac, vascular, pulmonary, or hematologic and/or surgical strategies and propose research that will significantly improve clinical outcomes of resuscitation efforts. Research plans should emphasize specialties such as medicine, surgery, imaging, computer science, bioengineering and materials science, chemistry and physics. This program will use the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) funding mechanisms. Because the length of time and cost of research involving advanced technology projects may exceed that normally awarded for SBIR/STTR grants, the National Heart, Lung, and Blood Institute (NHLBI) will allow well justified Phase I applications with a project period of up to two years and a budget not to exceed, including fixed fees, $150,000 per year total costs (maximum of $300,000 total costs for 2 years). Phase II applications in response to this Program Announcement (PA) will only be accepted as competing continuations of previously funded National Institutes of Health (NIH) Phase I SBIR/STTR awards. The previously funded Phase I award need not have been awarded under this PA but the Phase II proposal must be a logical extension of the Phase I research. The NHLBI will consider Phase II projects with a project period up to three years and a budget not to exceed $500,000 per year total costs, including fixed fees. This PA must be read in conjunction with the current calendar year publication of the Omnibus Solicitation of the Public Health Service for Small Business Innovation Research Grant Applications, and the Omnibus Solicitation of the National Institutes of Health for Small Business Technology Transfer Grant Applications: http://grants.nih.gov/grants/funding/sbirsttr1/index.pdf. All of the instructions within the Omnibus Solicitations apply with the following exceptions: o Opportunity for two years of Phase I support with a budget not to exceed $150,000 in total costs, including fixed fees, per year; o Opportunity for three years of Phase II support with a budget not to exceed $500,000 in total costs, including fixed fees, per year. HEALTHY PEOPLE 2010 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2010," a PHS led national activity for setting priority areas. This Program Announcement, "SBIR/STTR Technologies for Monitoring and Performing Resuscitation", is related to the priority areas of cardiovascular, lung, blood, and sleep disorders and diseases as well as additional priority areas. Potential applicants may obtain a copy of "Healthy People 2010" at http://www.health.gov/healthypeople/. ELIGIBILITY REQUIREMENTS Eligibility requirements for SBIR and STTR are described in the NIH Omnibus Solicitation for SBIR/STTR grant applications which is available on the Internet at: http://grants.nih.gov/grants/funding/sbirsttr1/index.pdf. MECHANISM OF SUPPORT This PA will use the NIH SBIR/STTR award mechanisms. Responsibility for the planning, direction, and execution of the proposed project will be solely that of the applicant organization. A. INDIVIDUAL PHASE I APPLICATIONS Phase I applications in response to this PA will be funded as Phase I SBIR Grants (R43) or Phase 1 STTR Grants (R41) with modifications as described below. Applications for Phase I grants should be prepared following the directions for Phase I SBIR/STTR applications as described in the Omnibus Solicitation which is available at: http://grants.nih.gov/grants/funding/sbirsttr1/index.pdf. Well-justified Phase I applications with a project period up to two years and a budget not to exceed $150,000 per year total cost, including fixed fees, (maximum of $300,000 total costs for two years) will be allowed. B. INDIVIDUAL PHASE II APPLICATIONS Phase II applications in response to this PA will be awarded as Phase II SBIR Grants (R44) or STTR Grants (R42) with modifications as described below. Phase II applications will only be accepted as competing continuations of previously funded NIH Phase I SBIR/STTR awards. The Phase II application must be a logical extension of the Phase I research and must be responsive to this PA. Applications for Phase II awards should be prepared following the instructions for NIH Phase II SBIR/STTR applications. The Phase II SBIR instructions and application may be found on the Internet at: http://grants.nih.gov/grants/funding/sbir2/index.htm. The Phase II STTR instructions and application may be found on the Internet at: http://grants.nih.gov/grants/funding/sttr2/index.html. Well-justified Phase II applications with a project period up to three years and a budget not to exceed $500,000 in total costs, including fixed fees, per year will be allowed. RESEARCH OBJECTIVES For the purpose of this solicitation resuscitation research will include the population of patients who collapse as a consequence of sudden circulatory, hypoxemic, or traumatic arrest. Circulatory, hypoxemic or traumatic arrest is a significant public health problem cutting across age, race, and gender. It often occurs without warning in persons who are healthy prior to their collapse. The national estimated mortality for all cause arrest is 350,000 lives per year, with economic costs for trauma related injuries estimated at over $400 billion dollars per year, in productive life years. In contrast to most problems in cardiovascular medicine, current death rates have not improved significantly despite scientific advances throughout medicine. In recognition of this public health burden, in June 2000, the NHLBI led a multi- agency conference entitled, "Post-Resuscitative and Initial Utility in Life Saving Efforts" (PULSE) co-sponsored by the National Institute of Child Health and Human Development (NICHD), the National Institute of General Medical Sciences (NIGMS), the National Institute of Neurological Disorders and Stroke (NINDS), of the National Institutes of Health (NIH), the Food and Drug Administration (FDA), and the Department of Defense (DOD). Nearly 200 conference participants, from the domestic and international scientific and practice community, spanning basic, applied, and trauma science expertise, met for two and a half days to identify obstacles and to forge a research agenda that would save lives and restore arrest victims to their pre-event neurologic and physical condition. Conference participants concluded new therapies and technologies to increase survival outcomes in resuscitation are realistic and should be fostered. A key obstacle for contemporary treatment strategies is the acutely limited time window for effective treatment. Beyond ten minutes after victim collapse, the likelihood of complete physical and neurologic recovery with conventional resuscitation is very low and overall survival for arrest victims is less than ten percent. Extension of therapeutic time windows and support of critical physiologic functions provides an opportunity to expand strategies for the treatment of arrest syndromes and for dramatic improvement in survival. The need to stimulate the development of enabling technology and new scientific avenues to expand basic and applied resuscitation research was a recurring theme throughout the Workshop deliberations. It became a key recommendation of the conference, and is the basis for this solicitation. The theoretical basis for cardiopulmonary resuscitation (CPR) practice, closed chest compressions and ventilation, was established in the 1960's. The fundamental strategies for CPR have not changed since these original concepts emerged and there is a paucity of contemporary CPR research. Outcomes in trauma related battlefield statistics have not improved significantly since the Civil War. Recognition of ventricular fibrillation, a common cause of circulatory arrest, and the efficacy of cardioversion in restoration of normal conduction and spontaneous circulation occurred in the 1940's. Despite numerous advances in the identification of patients at risk and the use of therapeutic interventions including drugs and devices the outcome of resuscitation efforts for arrest victims remains poor. Even with contemporary use of the automated external defibrillator to enhance successful patient discharge rates in controlled studies remains less than twenty percent. Survival is significantly lower if complete neurologic recovery is included. Existing strategies known to restore circulation, shorten ischemia, and save lives should be refined to encourage and facilitate rapid, widespread and effective out-of-hospital application and are encouraged by this announcement. Current investigations are limited by underutilization of systems correlations and understanding of interrelated factors which contribute to irreversible cellular, vascular and organ damage in arrest states. Expansion of basic and applied research with a goal of identifying new therapies to minimize or tolerate whole-body ischemic insults holds promise for a dramatic improvement in survival rates. Scientific evidence exists to support assumptions that metabolic modulation of cellular and tissue systems could improve survival. New therapeutic interventions are likely to be derived from an understanding of cellular biology and gene expression that provide protection or tolerance to ischemia, reperfusion injury and other derangements of inadequate perfusion. A critical obstacle to improve survival, particularly for out-of-hospital arrest, is the lack of methods and systems to identify, monitor, and trend physiologic (biochemical, metabolic or cellular) parameters. Noninvasive or minimally invasive devices to be applied in the field to detect blood and tissue oxygen, carbon dioxide levels, pH, blood pressure, and assess vital organ perfusion are desperately needed. These devices need to be interrelated and should not impede resuscitation efforts. Such technology would facilitate research, identify critical markers, or trends of these markers, and provide critical baselines for monitoring and assessment of arrests victim during resuscitation efforts. Rapid out-of-hospital application of a percutaneous, or noninvasive continuous flow circulatory support system with the ability to administer fluids and deliver medications can be vital to survival of arrest victims. Enhancement of survival outcomes following resuscitation and development and piloting of innovative strategies which may, directly or indirectly, effect this outcome is the primary goal of this announcement. The primary potential target is the control and/or alleviation of whole-body ischemia and reperfusion injury before, during, and following resuscitation. Several factors contribute to the eventual demise of heart, lung or vascular cells, including oxidant stress, calcium overload, osmotic stress, energy depletion, and inflammation. New therapeutic interventions may focus on addressing mechanisms of regional or whole-body ischemia and reperfusion to improve survival. Hypothermia successfully preserves cells, tissue, organs and organ systems in a variety of settings, however, there are hypothermia-related complications, including changes in electrical stability of the heart, clotting factors, blood chemistries and tissue oxygen that need further investigation. Research projects to evaluate novel methods to induce controlled hypothermia in the field or during resuscitation efforts, offer novel opportunities to increase the functional time window in resuscitation victims and significantly improve survival. Investigations in hibernation, birth, and shock, that are associated with sudden profound changes in circulation, metabolism, and basal physiologic processes may provide insight for new therapeutic or protective strategies for complete physiologic and neurocognitive recovery. Trauma arrest victims provide unique challenges and opportunities for resuscitation research. Thrombosis and hemorrhage control are critical in the care of trauma victims. Resuscitation can be successful only if hemostasis is achieved and delivery of critical substrate is adequately restored. The identification, development, and testing of an optimal resuscitation fluid, which can prolong tissue viability, whether a temporary or long-term substitute for blood derived products, would be a boon for trauma resuscitation survival outcomes. Innovative strategies or systems to provide rapid vascular access and appropriate replacement fluid delivery will be a major advance in reducing trauma related deaths. Noninvasive or minimally invasive imaging techniques providing rapid assessment of multiple vital organ function, volume status, or cellular or organ perfusion rates during resuscitation efforts is critical to assess patient status and would provide timely feedback to implement and assess appropriate treatment. Unwitnessed arrest or collapse in a public facility presents another critical resuscitation challenges. Instantaneous interactive communications systems, such as global positioning technology, is needed as a rapid alert system for paramedical personnel and to provide bystanders with instructions for initiation of life-saving resuscitation measures. This PA seeks to encourage potential applicants to take full advantage of the SBIR/STTR program mechanism for multi-disciplinary research projects that develop monitoring systems and approaches to perform resuscitation that are safe and effective for use in humans. In the pre-clinical or clinical development phases, collaborations with approved animal facilities and healthcare organizations may be required. Research proposals should focus on improving out-of-hospital resuscitation, but the need to evaluate specific technologies and approaches in the clinic during design development is recognized. This program seeks innovative projects to provide new capabilities in systems and methods. Projects that offer only incremental advances of existing in-hospital technologies will not be responsive to this PA. Examples of topics the research and clinical communities have identified are listed below: however this program announcement is not limited to these examples and is open to all relevant, meritorious research ideas: o Develop ultra fast methods for recognition and identification of patient collapse and location. o Design to improve defibrillator technology. o Develop enabling technologies for research of whole body ischemia and reperfusion injury in appropriate animals models and humans. o Develop methods to augment rapid delivery and transfer of oxygen to cells, tissues and organs. o Develop methods for rapid functional restoration of circulation, both neurologic and cardiovascular, during cardiac, hypoxemic and/or traumatic arrest. o Develop methods for rapid vascular access and delivery of medications and resuscitation fluids, either traditional or novel synthetic preparations o Develop materials and methods for rapid induction of controlled hypothermia o Develop alternative methods to traditional CPR to maintain vital organ blood flow and nutrient delivery during cardiac, hypoxemic, and/or traumatic arrest. o Develop biosensors, using natural and synthetic substrates, for acquisition and monitoring of critical vital organ function, (e.g. cardiac, neurologic, cellular and tissue oxygen levels). o Develop methods to rapidly identify and implement hemostasis in trauma victims. INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of the NIH that women and members of minority groups and their subpopulations must be included in all NIH supported biomedical and behavioral research projects involving human subjects, unless a clear and compelling rationale and justification are provided that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43). All investigators proposing research involving human subjects should read the UPDATED "NIH Guidelines For Inclusion of Women and Minorities as Subjects in Clinical Research," published in the NIH Guide for Grants and Contract shave been published in the Federal Register of March 28, 1994 (FR 59 14508-14513) and in the NIH Guide for Grants and Contracts, on August 2, 2000 (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-048.html); a complete copy of the updated Guidelines are available at http://grants.nih.gov/grants/funding/women_min/guidelines_update.htm: The revisions relate to NIH defined Phase III clinical trials and require: a) all applications or proposals and/or protocols to provide a description of plans to conduct analyses, as appropriate, to address differences by sex/gender and/or racial/ethnic groups, including subgroups if applicable; and b) all investigators to report accrual, and to conduct and report analyses, as appropriate, by sex/gender and/or racial/ethnic group differences. INCLUSION OF CHILDREN AS PARTICIPANTS IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of NIH that children (i.e., individuals under the age of 21) must be included in all human subjects research, conducted or supported by the NIH, unless there are scientific and ethical reasons not to include them. This policy applies to all initial applications submitted for receipt dates after October 1, 1998. All investigators proposing research involving human subjects should read the "NIH Policy and Guidelines on the Inclusion of Children as Participants in Research Involving Human Subjects" that was published in the NIH Guide for Grants and Contracts, March 6, 1998, and is available at the following URL address: http://grants.nih.gov/grants/guide/notice-files/not98-024.html Investigators also may obtain copies of these policies from the program staff listed under INQUIRIES. Program staff may also provide additional relevant information concerning the policy. URLS IN NIH GRANT APPLICATIONS OR APPENDICES All applications and proposals for NIH funding must be self-contained within specified page limitations. Unless otherwise specified in an NIH solicitation, Internet addresses (URLs) should not be used to provide information necessary to the review because reviewers are under no obligation to view the Internet sites. Reviewers are cautioned that their anonymity may be compromised when they directly access an Internet site. APPLICATION PROCEDURES OMNIBUS SOLICITATIONS for both the SBIR and STTR programs are available electronically through the NIH, Office of Extramural Research Small Business Funding Opportunities Web site at http://grants.nih.gov/grants/funding/sbir.htm. Hard copies are not available. Applicants planning to submit an SBIR or STTR Phase I or Phase II application AFTER April receipt dates should check the NIH Small Business Funding Opportunities is website http://grants.nih.gov/grants/funding/sbir.htm for more specific details and instructions. THE TITLE AND NUMBER OF THIS PA MUST BE TYPED IN LINE 2 ON THE FACE PAGE OF THE APPLICATION. For Phase I applications, applicants are strongly encouraged to highlight the innovation of their proposed research and to clearly state the milestones that will be used to demonstrate feasibility. For Phase II applications, the demonstration of feasibility accomplished in Phase I should be clearly indicated. The OMNIBUS SOLICITATIONS give the normal levels of support and period of time for SBIR and STTR Phase I and II awards. However, as stated under MECHANISM OF SUPPORT section, Phase I applications submitted in response to this PA can have a project period of up to two years and a budget not to exceed $150,000 per year direct costs, including fixed fees. The second year of the Phase I budget should be included on the Budget Justification page, using categorical totals if costs deviate significantly from the first year of the budget, with narrative justifications for the increase(s). If the second year simply escalates due to cost of living factors, a statement to that effect with the escalation factor should be included rather than categorical totals. Phase II applications submitted in response to this PA can have a project period no longer than three years with a budget up to $500,000 in total costs per year, including fixed fees. The total duration (Phase I and Phase II application) cannot exceed five years. An annual meeting of all investigators funded through this program will be held to share progress and research insights that may further progress in the program. Applicants should request travel funds in their budgets for the principal investigator and one additional young investigator to attend this annual meeting. Submit a signed, typewritten original of the application, including the Checklist, and two signed photocopies in one package to: CENTER FOR SCIENTIFIC REVIEW NATIONAL INSTITUTES OF HEALTH 6701 ROCKLEDGE DRIVE, ROOM 1040, MSC 7710 BETHESDA, MD 20892-7710 BETHESDA, MD 20817 (for express/courier service) REVIEW CONSIDERATIONS Phase I and Phase II applications submitted under this PA will be accepted after the date of issuance up until December 2003. There after, this initiative will be evaluated and a decision will be made as to whether the initiative will be re-announced.. Upon receipt, applications will be reviewed by the Center for Scientific Review for completeness. Applications not adhering to application instructions described above, and those applications that are incomplete as determined by the Center for Scientific Review, will be returned to the applicant without review. Applications that are complete and adhere to the guidelines of this PA will be evaluated for scientific and technical merit by an appropriate peer review group convened by the Center for Scientific Review in accordance with the review criteria stated below. As part of the initial merit review, all applicants will receive a written critique and may undergo a process in which only those applications deemed to have the highest scientific merit, generally the top half of the applications, will be discussed, assigned a priority score, and receive a second level review by the appropriate Advisory Council. Review Criteria Review criteria are described in the NIH Omnibus Solicitation and are described below and are available on the Internet at the following URL address: http://grants.nih.gov/grants/funding/sbirsttr1/index.pdf. The goals of NIH-supported research are to advance our understanding of biological systems, improve the control of disease, and enhance health. In the written comments reviewers will be asked to discuss the following aspects of the application in order to judge the likelihood that the proposed research will have a substantial impact on the pursuit of these goals. Each of these criteria will be addressed and considered in assigning the overall score, weighting them as appropriate for each application. Note that the application does not need to be strong in all categories to be judged likely to have major scientific impact and thus deserve a high priority score. For example, an investigator may propose to carry out important work that by its nature is essential to move a field forward but is not innovative. (1) Significance: Does the proposed project have commercial potential to lead to a marketable product or process? Does this study address an important problem? What may be the anticipated commercial and societal benefits of the proposed activity? If the aims of the application are achieved, how will scientific knowledge be advanced? Does the proposal lead to enabling technologies (e.g., instrumentation, software) for further discoveries? Will the technology have a competitive advantage over existing/alternate technologies that can meet the market needs? (2) Approach: Are the conceptual framework, design, methods, and analyses adequately developed, well-integrated, and appropriate to the aims of the project? Is the proposed plan a sound approach for establishing technical and commercial feasibility? Does the applicant acknowledge potential problem areas and consider alternative strategies? Are the milestones and evaluation procedures appropriate? (3) Innovation: Does the project challenge existing paradigms or employ novel technologies, approaches or methodologies? Are the aims original and innovative? (4 Investigators: Is the Principal Investigator capable of coordinating and managing the proposed SBIR/STTR? Is the work proposed appropriate to the experience level of the Principal Investigator and other researchers including consultants and sub-awardees (if any)? (5) Environment: Is there sufficient access to resources (e.g., equipment, facilities)? Does the scientific and technological environment in which the work will be done contribute to the probability of success? Do the proposed experiments take advantage of unique features of the scientific environment or employ useful collaborative arrangements? In accordance with NIH policy, all applications will also be reviewed with respect to the following: o The adequacy of plans to include both genders, minorities and their subgroups, and children, as well as any differences noted within subset analysis as to treatment strategies as appropriate for the scientific goals of the research. Plans for the recruitment and retention of subjects will also be evaluated. o The reasonableness of the proposed budget and duration in relation to the proposed research. o The adequacy of the proposed protection for humans, animals or the environment, to the extent they may be adversely affected by the project proposed in the application. AWARD CRITERIA Applications will compete for available funds with all other recommended SBIR and STTR applications. Funding decisions for Phase I will be based on quality of the proposed project as determined by peer review, availability of funds, and program priority. Phase II applications will be selected for funding based on the above criteria as well as peer review assessment of attainment of Phase I goals. INQUIRIES Inquiries are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Direct inquiries regarding programmatic issues to: Heart and Vascular Caroline C. Webb, MSN, CCRN Division of Heart and Vascular Diseases National Heart, Lung, and Blood Institute Rockledge II, Room 9174, MSC 7940 Bethesda, MD 20892-7940 Telephone: (301) 435-0515 FAX: (301) 480-1336 Email: webbca@nhlbi.nih.gov Pulmonary Ms. Ann Rothgeb Division of Lung Diseases National Heart, Lung, and Blood Institute Rockledge II, Room 101114, MSC 7952 Bethesda, MD 20892-7952 Telephone: (301) 435-0202 FAX: (301) 480-3557 Email: rothgeba@nih.gov Hematology and Blood Resources Henry Chang, M.D. Division of Blood Diseases and Resources Rockledge II, Room 10170 MSC 7950 Bethesda, MD 20892-7950 Telephone: (301) 435-0067 FAX: (301) 480-1060 Email: changh@nih.gov Epidemiology Lawton Cooper, M.D. Division of Epidemiology and Clinical Application Rockledge II, Room 8124 MSC 7936 Bethesda, MD 20892 Telephone: (301) 435-3077 FAX: (301) 480-1669 Email: cooperl@nih.gov Direct inquiries regarding fiscal matters to: Ms. Shelia Ortiz Division of Extramural Affairs Grants Operations Branch National Heart, Lung, and Blood Institute Rockledge II, Room 7154, MSC 7926 Bethesda, MD 20892-7926 Telephone: (301) 435-0166 FAX: (301) 480-3310 Email: Ortizs@nih.gov AUTHORITY AND REGULATIONS This program is described in the of Federal Domestic Assistance No. 93.837, 93.838, 93.839. Awards are made under authorization of sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and administered under NIH grants policies and Federal Regulations 42 CFR 52 and 45 CFR Parts 74 and 92. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. The PHS strongly encourages all grant and contract recipients to provide a smoke-free workplace and promote the non-use of all tobacco products. In addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, and portion of a facility) in which regular or routine education, library, day care, health care or early childhood development services are provided to children. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people.
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, RealPlayer, Video or Flash files, see Help Downloading Files. |